RecruitingPHASE1, PHASE2NCT06677229

Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury

Studying Spinal cord injury

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Technophage, SA
Intervention
Eletriptan HBr 40 mg(drug)
Enrollment
28 target
Eligibility
18-65 years · All sexes
Timeline
20252027

Study locations (2)

Collaborators

VectorB2B

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06677229 on ClinicalTrials.gov

Other trials for Spinal cord injury

Additional recruiting or active studies for the same condition.

See all trials for Spinal cord injury

← Back to all trials